Evidence map›Paper›PMID 27854264›Full record

ArticleJournal of clinical medicine2016

Integrated Exposure-Based Therapy for Co-Occurring Post Traumatic Stress Disorder (PTSD) and Substance Dependence: Predictors of Change in PTSD Symptom Severity.

Katherine L Mills, Emma L Barrett, Sabine Merz, Julia Rosenfeld, Philippa L Ewer, Claudia Sannibale, Amanda L Baker, Sally Hopwood, Sudie E Back, Kathleen T Brady and 1 more

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Katherine L MillsNational Drug & Alcohol Research Centre, University of New South Wales, Sydney 2052, NSW, Australia. k.mills@unsw.edu.au.
Emma L BarrettNational Drug & Alcohol Research Centre, University of New South Wales, Sydney 2052, NSW, Australia. e.barrett@unsw.edu.au.
Sabine MerzNational Drug & Alcohol Research Centre, University of New South Wales, Sydney 2052, NSW, Australia. sabinemerz@hotmail.com.
Julia RosenfeldNational Drug & Alcohol Research Centre, University of New South Wales, Sydney 2052, NSW, Australia. juliarosenfeld@hotmail.com.
Philippa L EwerNational Drug & Alcohol Research Centre, University of New South Wales, Sydney 2052, NSW, Australia. philippa.ewer@gmail.com.
Claudia SannibaleNational Drug & Alcohol Research Centre, University of New South Wales, Sydney 2052, NSW, Australia. claudia.sannibale@exemail.com.au.
Amanda L BakerSchool of Medicine and Public Health, University of Newcastle, Callaghan 2308, NSW, Australia. Amanda.Baker@newcastle.edu.au.
Sally HopwoodSchool of Psychology, University of New South Wales, Sydney 2052, NSW, Australia. s.hopwood@student.unsw.edu.au.
Sudie E BackDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC 29425, USA. backs@musc.edu.
Kathleen T BradyDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC 29425, USA. bradyk@musc.edu.
Maree TeessonNational Drug & Alcohol Research Centre, University of New South Wales, Sydney 2052, NSW, Australia. m.teesson@unsw.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This paper examines factors associated with change in PTSD symptom severity among individuals randomised to receive an integrated exposure-based psychotherapy for PTSD and substance dependence-Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE). Outcomes examined include change in PTSD symptom severity as measured by the Clinician Administered PTSD Scale (CAPS), and the reliability and clinical significance of change in PTSD symptom severity. Factors examined include patient baseline characteristics, treatment characteristics, and events over follow-up. The mean difference in CAPS score was 38.24 (SE 4.81). Approximately half (49.1%) demonstrated a reliable and clinically significant improvement in PTSD symptom severity. No one was classified as having demonstrated clinically significant worsening of symptoms. Three independent predictors of reductions in PTSD symptom severity were identified: baseline PTSD symptom severity (β 0.77,

Indexed as

comorbiditypost traumatic stress disorderpsychological treatment

Identifiers

PMID27854264
PMCPMC5126798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.